Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

(2017) Julian Walter Holch et al.   EUROPEAN JOURNAL OF CANCER

The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study

(2017) Jonna Berntsson et al.   INTERNATIONAL JOURNAL OF CANCER

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability

(2017) Hans Brunnström et al.   MODERN PATHOLOGY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

(2017) Junhun Cho et al.   Oncotarget

PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer

(2017) Yanhua Wu et al.   Oncotarget

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

(2017) Jan Willem Kleinovink et al.   OncoImmunology

PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer

(2017) Dagmar Kollmann et al.   OncoImmunology

PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis

(2016) Markus Hecht et al.   EUROPEAN JOURNAL OF CANCER

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer

(2016) Yohei Masugi et al.   GUT

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

(2016) John R. Webb et al.   GYNECOLOGIC ONCOLOGY

Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer

(2016) Jonna Berntsson et al.   INTERNATIONAL JOURNAL OF CANCER

Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma

(2016) Lik Hang Lee et al.   MODERN PATHOLOGY

PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes

(2016) Matthew W Rosenbaum et al.   MODERN PATHOLOGY

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

(2016) Yaqi Li et al.   Molecular Cancer

Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer

(2016) Lisha Wang et al.   Molecular Diagnosis & Therapy

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

(2016) Jin Sheng et al.   Scientific Reports

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients

(2016) Hye Ryun Kim et al.   Scientific Reports

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic review

(2015) G.H. Lee et al.   EJSO

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

(2015) Silvia Darb-Esfahani et al.   Oncotarget

PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity

(2015) Tong Seng Lim et al.   OncoImmunology

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer

(2013) Sakarias Wangefjord et al.   Diagnostic Pathology

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

(2013) Raoul A. Droeser et al.   EUROPEAN JOURNAL OF CANCER

Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study

(2013) Sakarias Wangefjord et al.   Biology of Sex Differences

A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer

(2012) J Eberhard et al.   BRITISH JOURNAL OF CANCER

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

(2012) Mai Yamauchi et al.   GUT

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer

(2011) A Larsson et al.   BRITISH JOURNAL OF CANCER

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Colorectal cancer, one entity or three

(2009) Feng-ying Li et al.   Journal of Zhejiang University-SCIENCE B

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

(2008) Paul Salama et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY